8-K Announcements
6Material company update
Mar 3, 2026·SEC
Material company update
Dec 17, 2025·SEC
Material company update
Dec 15, 2025·SEC
Immunome, Inc.(IMNM)Earnings, Financials & Key Ratios
IMNM•NASDAQ
$23.27
$2.63B mkt cap·Price updated May 6, 2026
AboutImmunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.Show more
- Revenue$7M-23.2%
- EBITDA-$224M+26.2%
- Net Income-$212M+27.5%
- EPS (Diluted)-2.43+51.4%
- EBITDA Margin-3228.83%+3.9%
- Operating Margin-3228.83%+4.5%
- Net Margin-3059.99%+5.6%
- ROE-52.09%+73.2%
- ROIC-1228.6%-75.4%
- Debt/Equity0.01-77.2%
IMNM Key Insights
Immunome, Inc. (IMNM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 85 (top 15%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 49.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IMNM Price & Volume
Immunome, Inc. (IMNM) stock price & volume — 10-year historical chart
Loading chart...
IMNM Growth Metrics
Immunome, Inc. (IMNM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-23.23%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM27.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM84.03%
Return on Capital
10 Years-153.12%
5 Years-114.53%
3 Years-134.25%
Last Year-54.39%
IMNM Recent Earnings
Immunome, Inc. (IMNM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 3/12 qtrs (38%)
Q2 2026Latest
Mar 3, 2026EPS
$0.75
Est $0.59
-27.1%
Revenue
—
Est $876,034
Q4 2025
Nov 6, 2025EPS
$0.65
Est $0.57
-14.0%
Revenue
—
Est $850,000
Q3 2025
Aug 6, 2025EPS
$0.50
Est $0.52
+3.8%
Revenue
$4M
Est $833,333
+381.8%
Q2 2025
May 12, 2025EPS
$0.52
Est $0.66
+21.2%
Revenue
$3M
Est $457,140
+540.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 3, 2026 | $0.75vs $0.59-27.1% | —vs $876,034 |
| Q4 2025 | Nov 6, 2025 | $0.65vs $0.57-14.0% | —vs $850,000 |
| Q3 2025 | Aug 6, 2025 | $0.50vs $0.52+3.8% | $4Mvs $833,333+381.8% |
| Q2 2025 | May 12, 2025 | $0.52vs $0.66+21.2% | $3Mvs $457,140+540.1% |
Based on last 12 quarters of dataView full earnings history →
IMNM Peer Comparison
Immunome, Inc. (IMNM) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 XNCR | 954.14M | 13.01 | -10.49 | 13.65% | -185.71% | -23.68% | 0.30 | |
 ALKS | 5.89B | 35.32 | 24.70 | -5.25% | 9.78% | 8.82% | 0.04 |
Compare IMNM vs Peers
Immunome, Inc. (IMNM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMNM Income Statement
Immunome, Inc. (IMNM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Revenue Growth % | - | - | - | - | - | - | -35.5% | -23.23% |
| Cost of Goods Sold | 521K | 615K | 755K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -521K▲ 0% | -615K▼ 18.0% | -755K▼ 22.8% | 0▲ 100.0% | 0▲ 0% | 14.02M▲ 0% | 9.04M▼ 35.5% | 0▼ 100.0% |
| Gross Margin % | - | - | - | - | - | 100% | 100% | - |
| Gross Profit Growth % | - | -18.04% | -22.76% | 100% | - | - | -35.5% | -100% |
| Operating Expenses | 7.74M | 10.35M | 11.51M | 25.2M | 36.9M | 123.55M | 314.84M | 231.05M |
| OpEx % of Revenue | - | - | - | - | - | 881.35% | 3482.37% | 3328.83% |
| Selling, General & Admin | 866K | 1.52M | 4.78M | 11.09M | 13.63M | 19.66M | 32.95M | 43.77M |
| SG&A % of Revenue | - | - | - | - | - | 140.23% | 364.51% | 630.57% |
| Research & Development | 6.88M | 8.82M | 6.73M | 14.11M | 23.27M | 23.09M | 129.54M | 10M |
| R&D % of Revenue | - | - | - | - | - | 164.71% | 1432.83% | 144.07% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 80.8M | 152.34M | 177.29M |
| Operating Income | -7.74M▲ 0% | -10.35M▼ 33.6% | -12.26M▼ 18.5% | -25.2M▼ 105.6% | -36.9M▼ 46.4% | -109.53M▼ 196.8% | -305.8M▼ 179.2% | -224.11M▲ 26.7% |
| Operating Margin % | - | - | - | - | - | -781.35% | -3382.37% | -3228.83% |
| Operating Income Growth % | - | -33.64% | -18.49% | -105.56% | -46.41% | -196.82% | -179.19% | 26.71% |
| EBITDA | -7.22M | -9.73M | -11.51M | -24.45M | -36.27M | -108.8M | -303.7M | -224.11M |
| EBITDA Margin % | - | - | - | - | - | -776.16% | -3359.12% | -3228.83% |
| EBITDA Growth % | - | -34.77% | -18.22% | -112.49% | -48.35% | -199.98% | -179.13% | 26.21% |
| D&A (Non-Cash Add-back) | 521K | 615K | 755K | 755K | 631K | 728K | 2.1M | 0 |
| EBIT | -7.7M | -10.34M | -17.8M | -25.2M | -36.9M | -28.73M | -153.46M | 0 |
| Net Interest Income | -102K | -96K | -37K | 0 | 0 | 2.72M | 12.84M | 0 |
| Interest Income | 39K | 10K | 1K | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 141K | 106K | 38K | 10K | 5K | 0 | 0 | 0 |
| Other Income/Expense | -102K | -96K | -5.58M | 493K | 5K | 2.72M | 12.84M | 11.72M |
| Pretax Income | -7.84M▲ 0% | -10.44M▼ 33.1% | -17.84M▼ 70.8% | -24.71M▼ 38.5% | -36.9M▼ 49.3% | -106.81M▼ 189.5% | -292.96M▼ 174.3% | -212.39M▲ 27.5% |
| Pretax Margin % | - | - | - | - | - | -761.92% | -3240.38% | -3059.99% |
| Income Tax | 39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.5% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.84M▲ 0% | -10.55M▼ 34.5% | -17.84M▼ 69.1% | -24.71M▼ 38.5% | -36.9M▼ 49.3% | -106.81M▼ 189.5% | -292.96M▼ 174.3% | -212.39M▲ 27.5% |
| Net Margin % | - | - | - | - | - | -761.92% | -3240.38% | -3059.99% |
| Net Income Growth % | - | -34.48% | -69.07% | -38.54% | -49.31% | -189.48% | -174.29% | 27.5% |
| Net Income (Continuing) | -7.84M | -10.44M | -17.84M | -24.71M | -36.9M | -106.81M | -292.96M | -212.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7.18▲ 0% | -1.84▲ 74.4% | -1.69▲ 8.2% | -2.14▼ 26.6% | -3.09▼ 44.4% | -5.38▼ 74.1% | -5.00▲ 7.1% | -2.43▲ 51.4% |
| EPS Growth % | - | 74.37% | 8.15% | -26.63% | -44.39% | -74.11% | 7.06% | 51.4% |
| EPS (Basic) | -7.18 | -1.84 | -1.69 | -2.14 | -3.09 | -5.38 | -5.00 | -2.43 |
| Diluted Shares Outstanding | 1.09M | 5.74M | 10.11M | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Basic Shares Outstanding | 1.09M | 5.74M | 10.11M | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
IMNM Balance Sheet
Immunome, Inc. (IMNM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.11M | 3.12M | 42.89M | 56.64M | 22.65M | 144.7M | 221.34M | 660.78M |
| Cash & Short-Term Investments | 1.6M | 2.54M | 39.77M | 49.23M | 20.32M | 138.14M | 217.3M | 653.48M |
| Cash Only | 1.6M | 2.54M | 39.77M | 49.23M | 20.32M | 98.68M | 143.35M | 653.48M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 39.46M | 73.95M | 0 |
| Accounts Receivable | 0 | 0 | 850K | 4.31M | 847K | 289K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | 7.53 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 509K | 0 | 0 | 0 | 0 | 4.99M | 4.04M | 7.29M |
| Total Non-Current Assets | 2.34M | 1.94M | 1.63M | 1.29M | 1.4M | 3.84M | 18.9M | 22.41M |
| Property, Plant & Equipment | 2.08M | 1.7M | 1.53M | 855K | 965K | 3.64M | 14.39M | 17.61M |
| Fixed Asset Turnover | - | - | - | - | - | 3.85x | 0.63x | 0.39x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 100K | 0 | 100K | 100K | 0 | 100K | 0 | 0 |
| Other Non-Current Assets | 155K | 238K | 0 | 332K | 432K | 100K | 4.51M | 4.8M |
| Total Assets | 4.45M▲ 0% | 5.06M▲ 13.8% | 44.52M▲ 779.9% | 57.92M▲ 30.1% | 24.05M▼ 58.5% | 148.54M▲ 517.7% | 240.24M▲ 61.7% | 683.19M▲ 184.4% |
| Asset Turnover | - | - | - | - | - | 0.09x | 0.04x | 0.01x |
| Asset Growth % | - | 13.76% | 779.94% | 30.1% | -58.49% | 517.73% | 61.73% | 184.38% |
| Total Current Liabilities | 1.56M | 1.67M | 3.04M | 9.73M | 7.33M | 21.83M | 54.31M | 44.99M |
| Accounts Payable | 473K | 548K | 1.19M | 3.08M | 2.4M | 3.31M | 14.19M | 3.34M |
| Days Payables Outstanding | 331.37 | 325.24 | 573.85 | - | - | - | - | - |
| Short-Term Debt | 225K | 212K | 479K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 10.49M | 6.94M | 0 |
| Other Current Liabilities | 83K | 426K | 527K | 2.02M | 1.96M | 4.98M | 8M | 44.99M |
| Current Ratio | 1.35x | 1.88x | 14.12x | 5.82x | 3.09x | 6.63x | 4.08x | 14.69x |
| Quick Ratio | 1.35x | 1.88x | 14.12x | 5.82x | 3.09x | 6.63x | 4.08x | 14.69x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 28.09M | 39.02M | 142K | 12K | 62K | 6.83M | 4.77M | 3.85M |
| Long-Term Debt | 325K | 113K | 134K | 0 | 0 | 0 | 0 | 3.85M |
| Capital Lease Obligations | 239K | 0 | 0 | 0 | 62K | 1.34M | 4.77M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | -5.49M | 0 | 0 |
| Other Non-Current Liabilities | 27.53M | 38.91M | 8K | 12K | 0 | 5.49M | 0 | 0 |
| Total Liabilities | 29.65M | 40.69M | 3.18M | 9.74M | 7.39M | 28.66M | 59.08M | 48.84M |
| Total Debt | 1.18M | 564K | 613K | 317K | 291K | 1.65M | 4.83M | 3.85M |
| Net Debt | -426K | -1.98M | -39.15M | -48.91M | -20.03M | -97.03M | -138.52M | -649.63M |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.02x | 0.01x | 0.03x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -54.91x | -97.62x | -322.66x | -2520.40x | -7380.20x | - | - | - |
| Total Equity | -25.2M▲ 0% | -35.63M▼ 41.4% | 41.34M▲ 216.0% | 48.19M▲ 16.5% | 16.65M▼ 65.4% | 119.88M▲ 619.9% | 181.16M▲ 51.1% | 634.34M▲ 250.1% |
| Equity Growth % | - | -41.36% | 216.04% | 16.54% | -65.44% | 619.88% | 51.12% | 250.15% |
| Book Value per Share | -23.07 | -6.20 | 4.09 | 4.18 | 1.37 | 6.04 | 3.09 | 7.26 |
| Total Shareholders' Equity | -25.2M | -35.63M | 41.34M | 48.19M | 16.65M | 119.88M | 181.16M | 634.34M |
| Common Stock | 1K | 0 | 1K | 1K | 1K | 4K | 6K | 11K |
| Retained Earnings | -26.11M | -36.56M | -54.39M | -79.11M | -116M | -222.81M | -515.77M | -728.16M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -904K | 0 | -44.52M | -57.92M | 0 | 22K | 57K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMNM Cash Flow Statement
Immunome, Inc. (IMNM) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.41M | -9.6M | -12.13M | -18.23M | -28.69M | -7.57M | -110.79M | -190.92M |
| Operating CF Margin % | - | - | - | - | - | -53.99% | -1225.46% | -2750.6% |
| Operating CF Growth % | - | -29.62% | -26.4% | -50.21% | -57.41% | 73.62% | -1363.98% | -72.32% |
| Net Income | -7.84M | -10.44M | -17.84M | -24.71M | -36.9M | -106.81M | -292.96M | -212.39M |
| Depreciation & Amortization | 521K | 615K | 755K | 755K | 631K | 728K | 2.1M | 2.96M |
| Stock-Based Compensation | 11K | 14K | 621K | 3.45M | 5.33M | 6.22M | 15.75M | 25.69M |
| Deferred Taxes | 0 | 0 | 5.54M | -500K | -7.27M | 0 | 0 | 0 |
| Other Non-Cash Items | 9K | 3K | -2K | 4K | 7.27M | 80.29M | 149.44M | -7.17M |
| Working Capital Changes | -102K | 212K | -1.21M | 2.78M | 2.24M | 12M | 14.87M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 146K | 75K | 504K | 1.78M | -677K | -608K | 9.53M | -9.16M |
| Cash from Investing | -228K | -233K | -586K | -79K | -248K | -30.48M | -85.06M | 60.8M |
| Capital Expenditures | -228K | -233K | -586K | -79K | -248K | -831K | -7.17M | -9.69M |
| CapEx % of Revenue | - | - | - | - | - | 5.93% | 79.34% | 139.53% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 9.28M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | -46.34M | -6.25M |
| Cash from Financing | -551K | 10.77M | 49.94M | 27.77M | 32K | 116.41M | 240.53M | 640.36M |
| Debt Issued (Net) | -551K | 6.19M | 49K | -113K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 32K | 34K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -35K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -6M | 656K | 0 | 116.37M | -9.47M | 640.36M |
| Net Change in Cash | -8.19M▲ 0% | 941K▲ 111.5% | 37.22M▲ 3855.7% | 9.46M▼ 74.6% | -28.91M▼ 405.5% | 78.36M▲ 371.1% | 44.67M▼ 43.0% | 510.24M▲ 1042.2% |
| Free Cash Flow | -7.63M▲ 0% | -9.83M▼ 28.8% | -12.72M▼ 29.4% | -18.3M▼ 43.9% | -28.94M▼ 58.1% | -8.4M▲ 71.0% | -164.3M▼ 1856.2% | -200.6M▼ 22.1% |
| FCF Margin % | - | - | - | - | - | -59.92% | -1817.3% | -2890.13% |
| FCF Growth % | - | -28.81% | -29.36% | -43.91% | -58.09% | 70.98% | -1856.21% | -22.09% |
| FCF per Share | -6.99 | -1.71 | -1.26 | -1.59 | -2.39 | -0.42 | -2.80 | -2.30 |
| FCF Conversion (FCF/Net Income) | 0.94x | 0.91x | 0.68x | 0.74x | 0.78x | 0.07x | 0.38x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMNM Key Ratios
Immunome, Inc. (IMNM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -624.22% | -55.2% | -113.81% | -156.45% | -194.63% | -52.09% |
| Return on Invested Capital (ROIC) | - | - | - | -2580.61% | - | -843.66% | -700.32% | -1228.6% |
| Gross Margin | - | - | - | - | - | 100% | 100% | - |
| Net Margin | - | - | - | - | - | -761.92% | -3240.38% | -3059.99% |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.02x | 0.01x | 0.03x | 0.01x |
| Interest Coverage | -54.91x | -97.62x | -322.66x | -2520.40x | -7380.20x | - | - | - |
| FCF Conversion | 0.94x | 0.91x | 0.68x | 0.74x | 0.78x | 0.07x | 0.38x | 0.90x |
| Revenue Growth | - | - | - | - | - | - | -35.5% | -23.23% |
IMNM SEC Filings & Documents
Immunome, Inc. (IMNM) SEC filings — annual & quarterly reports (10-K, 10-Q)
IMNM Frequently Asked Questions
Immunome, Inc. (IMNM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immunome, Inc. (IMNM) reported $6.9M in revenue for fiscal year 2025.
Immunome, Inc. (IMNM) saw revenue decline by 23.2% over the past year.
Immunome, Inc. (IMNM) reported a net loss of $212.4M for fiscal year 2025.
Dividend & Returns
Immunome, Inc. (IMNM) has a return on equity (ROE) of -52.1%. Negative ROE indicates the company is unprofitable.
Immunome, Inc. (IMNM) had negative free cash flow of $200.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More IMNM
Immunome, Inc. (IMNM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates